TITLE

GRAFFINITY SIGNS COLLABORATION AGREEMENT WITH ELI LILLY

PUB. DATE
September 2002
SOURCE
Worldwide Biotech;Sep2002, Vol. 14 Issue 9, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Looks at the agreement signed by Graffinity Pharmaceuticals with Eli Lilly and Company.
ACCESSION #
7248250

 

Related Articles

  • Catalytica Formulates for Lilly. Moore, Samuel K. // Chemical Week;4/21/1999, Vol. 161 Issue 15, p10 

    Focuses on the agreement signed by Catalytica Pharmaceuticals with Eli Lilly for the formulation, filling and finishing of a Lilly drug candidate. Guaranteed revenues of Catalytica on the agreement; Service to be offered by Catalytica on the contract.

  • Analysts: Isis?Lilly deal validates antisense. Niiler, Eric // Nature Biotechnology;Oct2001, Vol. 19 Issue 10, p898 

    Reports on the deal between Eli Lilly and Co. and Isis Pharmaceuticals Inc. Cash payment by Lilly for rights to a non-small-cell lung cancer drug; Four-year drug discovery collaboration; Benefits of the deal for both companies.

  • Petnet to distribute Lilly's molecular imaging agent.  // Medical Device Daily;11/8/2011, Vol. 15 Issue 214, p9 

    The article reports on the commercial agreement signed by Petnet Solutions with Eli Lilly for the distribution of Lilly's molecular imaging agent.

  • Starpharma and Eli Lilly to collaborate on drug delivery. Desjardins, Lisa // Chemistry in Australia;Apr2010, Vol. 77 Issue 3, p7 

    The article offers information on the agreement of Starpharma for the use of its dendrimer technology to improve the pharmaceutical products of Eli Lilly and Co.

  • Lilly, Alkermes in Deal.  // Chemical Market Reporter;2/25/2002, Vol. 261 Issue 8, p36 

    Reports on the contract signed by Eli Lilly and Co. with Alkermes Inc. Investment of Eli Lilly on Alkermes; Net loss posted by Alkermes for the period that ended December 31, 2001.

  • Lilly and Sibia In Three-Year Deal.  // Chemical Market Reporter;05/31/99, Vol. 255 Issue 22, p11 

    Provides information on the agreement entered by Eli Lilly & Co. with Sibia Neurosciences Inc. Purpose of the deal; Terms under the agreement.

  • The Lilly way. Miller, Jim // Pharmaceutical Technology Europe;May2010, Vol. 22 Issue 5, p12 

    The article reports that Eli Lilly and Company has formed several strategic outsourcing relationships to help reduce its fixed cost structure while providing quality development and manufacturing services. The company has launched the fully integrated pharmaceutical network strategy in order for...

  • Eli Lilly, Medtronic co-research new approach to Parkinson's.  // Medical Device Daily;4/27/2011, Vol. 15 Issue 81, p2 

    The article reports on the research and development agreement between Eli Lilly and Medtronic for the treatment of Parkinson's disease.

  • MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab. Young, Donna // BioWorld Today;10/19/2007, Vol. 18 Issue 204, p1 

    The article reports on the deal between MacroGenics Inc. and Eli Lilly and Co. to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. Exclusive rights to teplizumab will be acquired by Eli Lilly under the agreement. The safety and efficacy of three teplizumab dosing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics